J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jafron Biomedical Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Free Cash Flow
ÂĄ926.5m
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Free Cash Flow
ÂĄ487m
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Free Cash Flow
ÂĄ1.7B
CAGR 3-Years
42%
CAGR 5-Years
67%
CAGR 10-Years
49%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Free Cash Flow
ÂĄ12.5B
CAGR 3-Years
22%
CAGR 5-Years
26%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Free Cash Flow
ÂĄ159m
CAGR 3-Years
-57%
CAGR 5-Years
-33%
CAGR 10-Years
-1%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Free Cash Flow
-ÂĄ943.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Free Cash Flow?
Free Cash Flow
926.5m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Free Cash Flow amounts to 926.5m CNY.

What is Jafron Biomedical Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
32%

Over the last year, the Free Cash Flow growth was 52%. The average annual Free Cash Flow growth rates for Jafron Biomedical Co Ltd have been 17% over the past three years , 32% over the past five years .

Back to Top